The Concept of the Polypill in the Prevention of Cardiovascular Disease

Background: Cardiovascular disease (CVD) is a global epidemic and the largest cause of noncommunicable disease–related death worldwide. The concept of a combination pill, or “polypill,” composed of aspirin, antihypertensives, and a statin has been suggested to simplify and improve the prevention and...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Brandon Wiley, Valentin Fuster
Formato:	article
Lenguaje:	EN
Publicado:	Ubiquity Press 2014
Materias:	cardiovascular disease polypill prevention public health Infectious and parasitic diseases RC109-216 Public aspects of medicine RA1-1270
Acceso en línea:	https://doaj.org/article/3e4fb370c49d47dc92409e2dffe445ee
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3e4fb370c49d47dc92409e2dffe445ee
record_format	dspace
spelling	oai:doaj.org-article:3e4fb370c49d47dc92409e2dffe445ee2021-12-02T02:55:12ZThe Concept of the Polypill in the Prevention of Cardiovascular Disease2214-999610.1016/j.aogh.2013.12.008https://doaj.org/article/3e4fb370c49d47dc92409e2dffe445ee2014-04-01T00:00:00Zhttps://annalsofglobalhealth.org/articles/54https://doaj.org/toc/2214-9996Background: Cardiovascular disease (CVD) is a global epidemic and the largest cause of noncommunicable disease–related death worldwide. The concept of a combination pill, or “polypill,” composed of aspirin, antihypertensives, and a statin has been suggested to simplify and improve the prevention and treatment of CVD. Individually, these medications have been shown to effectively modify risk factors of CVD, and a single pill composed of these medications has the potential to conveniently and cost effectively provide additive benefits in relative risk reduction. In particular, the polypill concept presents significant potential for reducing the impact of cardiovascular disease in low- and middle-income countries where populations account for >80% of all CVD-related deaths worldwide. Using a polypill as the primary way to prevent CVD has been proposed as a broad “vaccination” strategy to treat asymptomatic individuals based solely on age or the presence of risk factors. Findings: Several clinical trials have shown that combination pills are well tolerated and have lower relative risk by as much as 60–70% by moderately reducing blood pressure and LDL-cholesterol. However, uncertainty remains in regards to long-term adherence, cost effectiveness, and “medicalization” of asymptomatic individuals, who account for a large percentage of the world's population. Furthermore, more data regarding CVD outcomes is required to evaluate the widespread use of a polypill in primary prevention. Conclusion: The use of a combination pill in individuals with overt CVD provides the potential to reduce the “treatment gap” that exists in the secondary prevention of CVD by simplifying treatment algorithms, reducing nonadherence, and improving access to medications in countries lacking adequate healthcare infrastructure. The promising results of completed clinical trials have lead to the approval of polypill formulations (e.g., Polycap, Trinomia®, or Zycad) and several large clinical trials are posed to present new data regarding outcomes and adherence.Brandon WileyValentin FusterUbiquity Pressarticlecardiovascular diseasepolypillpreventionpublic healthInfectious and parasitic diseasesRC109-216Public aspects of medicineRA1-1270ENAnnals of Global Health, Vol 80, Iss 1, Pp 24-34 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	cardiovascular disease polypill prevention public health Infectious and parasitic diseases RC109-216 Public aspects of medicine RA1-1270
spellingShingle	cardiovascular disease polypill prevention public health Infectious and parasitic diseases RC109-216 Public aspects of medicine RA1-1270 Brandon Wiley Valentin Fuster The Concept of the Polypill in the Prevention of Cardiovascular Disease
description	Background: Cardiovascular disease (CVD) is a global epidemic and the largest cause of noncommunicable disease–related death worldwide. The concept of a combination pill, or “polypill,” composed of aspirin, antihypertensives, and a statin has been suggested to simplify and improve the prevention and treatment of CVD. Individually, these medications have been shown to effectively modify risk factors of CVD, and a single pill composed of these medications has the potential to conveniently and cost effectively provide additive benefits in relative risk reduction. In particular, the polypill concept presents significant potential for reducing the impact of cardiovascular disease in low- and middle-income countries where populations account for >80% of all CVD-related deaths worldwide. Using a polypill as the primary way to prevent CVD has been proposed as a broad “vaccination” strategy to treat asymptomatic individuals based solely on age or the presence of risk factors. Findings: Several clinical trials have shown that combination pills are well tolerated and have lower relative risk by as much as 60–70% by moderately reducing blood pressure and LDL-cholesterol. However, uncertainty remains in regards to long-term adherence, cost effectiveness, and “medicalization” of asymptomatic individuals, who account for a large percentage of the world's population. Furthermore, more data regarding CVD outcomes is required to evaluate the widespread use of a polypill in primary prevention. Conclusion: The use of a combination pill in individuals with overt CVD provides the potential to reduce the “treatment gap” that exists in the secondary prevention of CVD by simplifying treatment algorithms, reducing nonadherence, and improving access to medications in countries lacking adequate healthcare infrastructure. The promising results of completed clinical trials have lead to the approval of polypill formulations (e.g., Polycap, Trinomia®, or Zycad) and several large clinical trials are posed to present new data regarding outcomes and adherence.
format	article
author	Brandon Wiley Valentin Fuster
author_facet	Brandon Wiley Valentin Fuster
author_sort	Brandon Wiley
title	The Concept of the Polypill in the Prevention of Cardiovascular Disease
title_short	The Concept of the Polypill in the Prevention of Cardiovascular Disease
title_full	The Concept of the Polypill in the Prevention of Cardiovascular Disease
title_fullStr	The Concept of the Polypill in the Prevention of Cardiovascular Disease
title_full_unstemmed	The Concept of the Polypill in the Prevention of Cardiovascular Disease
title_sort	concept of the polypill in the prevention of cardiovascular disease
publisher	Ubiquity Press
publishDate	2014
url	https://doaj.org/article/3e4fb370c49d47dc92409e2dffe445ee
work_keys_str_mv	AT brandonwiley theconceptofthepolypillinthepreventionofcardiovasculardisease AT valentinfuster theconceptofthepolypillinthepreventionofcardiovasculardisease AT brandonwiley conceptofthepolypillinthepreventionofcardiovasculardisease AT valentinfuster conceptofthepolypillinthepreventionofcardiovasculardisease
_version_	1718402035784613888

The Concept of the Polypill in the Prevention of Cardiovascular Disease

Ejemplares similares